Matches in Wikidata for { <http://www.wikidata.org/entity/Q92730705> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q92730705 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q92730705 description "scientific article published on 13 February 2020" @default.
- Q92730705 description "wetenschappelijk artikel" @default.
- Q92730705 description "наукова стаття, опублікована 13 лютого 2020" @default.
- Q92730705 name "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 name "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 type Item @default.
- Q92730705 label "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 label "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 prefLabel "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 prefLabel "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 P1433 Q92730705-3C1DCFAD-DA72-4BA9-BB7B-DD861AB18FF5 @default.
- Q92730705 P1476 Q92730705-6652E724-60F5-489B-87EC-4BD8D7E14855 @default.
- Q92730705 P2093 Q92730705-1F979B5A-5580-4C00-A40C-E8B53ACF62E6 @default.
- Q92730705 P2093 Q92730705-4694B849-6958-499B-9DE9-4318A9E189A3 @default.
- Q92730705 P2093 Q92730705-5D221DE6-2D39-445D-B91D-4585EE717CAC @default.
- Q92730705 P2093 Q92730705-77FC9905-A06E-4F77-ADE0-8EF58D745410 @default.
- Q92730705 P2093 Q92730705-BC8DB404-4F03-474B-BCCE-C4FF8DA5E44A @default.
- Q92730705 P2093 Q92730705-C7FC5DF5-C29E-4FFB-836E-BB2B503AAA67 @default.
- Q92730705 P2093 Q92730705-EC03F614-4BFD-4A86-8357-29C610F474D3 @default.
- Q92730705 P275 Q92730705-D0097883-20D4-4E05-A7FA-887E5637DDA6 @default.
- Q92730705 P304 Q92730705-911E3D57-6DE1-43CA-AA4C-6426C831021A @default.
- Q92730705 P31 Q92730705-770F0E4E-53E1-481A-9F26-C391D0198F7E @default.
- Q92730705 P356 Q92730705-E68E2F7C-2ABF-469D-A641-F97CA4FAE8CB @default.
- Q92730705 P577 Q92730705-89E76A71-E638-43A6-8392-83F98A4C8941 @default.
- Q92730705 P6216 Q92730705-B47B3F21-0455-45C4-B19B-086F1E95CC10 @default.
- Q92730705 P698 Q92730705-3A912A4A-C914-4952-ABC2-2F343C711E6B @default.
- Q92730705 P921 Q92730705-C6B90CEC-4267-4915-9A03-EA9E0A9EDE49 @default.
- Q92730705 P921 Q92730705-D798F25D-BE12-4692-91F1-52633FA26CB0 @default.
- Q92730705 P356 13696998.2020.1718156 @default.
- Q92730705 P698 31951770 @default.
- Q92730705 P1433 Q6295521 @default.
- Q92730705 P1476 "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France" @default.
- Q92730705 P2093 "Federico Felizzi" @default.
- Q92730705 P2093 "Maurice Perol" @default.
- Q92730705 P2093 "Mazaleyrat Benjamin" @default.
- Q92730705 P2093 "Noman Paracha" @default.
- Q92730705 P2093 "Plommet Nicolas" @default.
- Q92730705 P2093 "Roze Stéphane" @default.
- Q92730705 P2093 "Sivignon Marine" @default.
- Q92730705 P275 Q24082749 @default.
- Q92730705 P304 "1-10" @default.
- Q92730705 P31 Q13442814 @default.
- Q92730705 P356 "10.1080/13696998.2020.1718156" @default.
- Q92730705 P577 "2020-02-13T00:00:00Z" @default.
- Q92730705 P6216 Q50423863 @default.
- Q92730705 P698 "31951770" @default.
- Q92730705 P921 Q3658562 @default.
- Q92730705 P921 Q420436 @default.